22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
IPO Year:
Exchange: AMEX
Website: xxiicentury.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2022 | $5.00 | Buy | Alliance Global Partners |
| 6/15/2022 | $5.00 | Buy | Craig Hallum |
| 3/8/2022 | $6.00 | Buy | Roth Capital |
| 7/23/2021 | $5.00 | Outperform | Cowen |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00
Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00
Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00
Cowen initiated coverage of 22nd Century Group with a rating of Outperform and set a new price target of $5.00
10-Q - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
424B5 - 22nd Century Group, Inc. (0001347858) (Filer)
DEF 14A - 22nd Century Group, Inc. (0001347858) (Filer)
EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)
424B5 - 22nd Century Group, Inc. (0001347858) (Filer)
424B5 - 22nd Century Group, Inc. (0001347858) (Filer)
S-3 - 22nd Century Group, Inc. (0001347858) (Filer)
S-8 - 22nd Century Group, Inc. (0001347858) (Filer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second
Fastest customizable press release news feed in the world
Initial 60-Store California Entry Extends XXII's Reduced-Nicotine Rollout Into One of the Nation's Largest and Most Influential Tobacco Markets, With a Pathway to Broader Expansion MOCKSVILLE, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the expansion of Pinnacle VLN® into the state of California through an initial approximately 60-store retail trial, establishing the brand's first retail presence in the state and opening another strategically important market for the Company's FDA-authorized reduced-nicotine cigarette platform. The Californi
New Product Introduction Broadens XXII's Fast-Scaling Pinnacle Brand Reinforcing Brand Power, Opening New Retail Doors, and Strengthening the Company's Revenue and Margin Expansion Story MOCKSVILLE, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the launch of Pinnacle Pure, a new tobacco and water style combustible cigarette, further expanding the Company's growing family of Pinnacle branded products, expected to be sold through multiple top national retailers in the United States and over 2,000 locations. The expected launch of Pinnacle Pure
VLN® Product Launch in Over 150 New High-Visibility Store Locations Positions XXII to Introduce VLN® to New Consumers and Potentially Capture a Large Adult-Smoker Market, Accelerate High-Margin Revenue MOCKSVILLE, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced that shipments are expected to commence of its Pinnacle VLN® cigarette brand for sale through one of the nation's largest purveyors of cigarettes in the US, with distribution expanding to almost 150 stores concentrated in the metro New York area and northern New Jersey. This new rollout m
FDA filing covers renewal applications for VLN® King and VLN® Menthol King, the first combusted cigarettes authorized as Modified Risk Tobacco Products, as 22nd Century advances its regulatory pathway for continued modified risk marketing status MOCKSVILLE, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco harm reduction company focused on reduced nicotine innovation, today highlighted that the U.S. Food and Drug Administration has filed for scientific review two Modified Risk Tobacco Product, or MRTP, renewal applications for the Company's VLN® King and VLN® Menthol King combusted, filtered cigarettes. The FDA filing marks an important step in the r
Continues VLN® Commercial Expansion with New Stores Selling Proprietary Branded VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the first quarter ended March 31, 2026, and provided an update on recent business highlights. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 2
MOCKSVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction,, will host a webcast on Thursday, May 7, 2026, at 8:00 AM ET to discuss its 2026 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results, discuss progress made in the first quarter and update plans for the 2026 year. The live and archived webcast will be accessible on th
Chairman & CEO Larry Firestone Details 2026 Priorities and Shareholder Value Strategy MOCKSVILLE, N.C., April 29, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today issued the following letter to stockholders from Lawrence Firestone, the Chairman and Chief Executive Officer of 22nd Century Group, Inc.: Dear Fellow Stockholders, As I reflect on the past year, I am proud of the progress our team has made to form the foundation of the future 22nd Century Group and position the company for long-term growth and success. No
MOCKSVILLE, N.C., April 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine reduction and plant biotechnology, today announced corporate updates regarding a new testing services agreement with North Carolina State University aimed at validating tobacco varieties featuring improved leaf quality and increased crop yields with the same low-nicotine content. The initiative builds upon 22nd Century's proprietary reduced nicotine content technology platform, which utilizes advanced plant breeding and biotechnology to reduce nicotine content in tobacco to minimally addictive levels. The Company's reduced nicotine tobacco is the foun
Company to Pursue Additional PMTA Submissions, Building on Its Status as the Only Holder of an FDA-Authorized Low Nicotine Combustible Cigarette Branded as VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Address Wider Consumer Preference and Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced an update on the advancement of a 100mm VLN® reduced nicotine content cigarette. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who w
VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci
This live feed shows all institutional transactions in real time.
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
Live finance-specific insights
Continues VLN® Commercial Expansion with New Stores Selling Proprietary Branded VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the first quarter ended March 31, 2026, and provided an update on recent business highlights. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 2
VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci
Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March
Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o
VLN® Early Adoption Commercial Activity Expands with Two Partner Brand Launches in Progress – Smoker Friendly and Pinnacle Commenced Pinnacle VLN® Stocking Shipments for Almost 1,000 Locations of Top-5 C-Store Customer, Additional Locations to Come Significantly Expanded State Authorizations for both Reduced Nicotine Content and Conventional Products High Margin Branded Products Business Model Set to Grow Profitably MOCKSVILLE, N.C., Aug. 14, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for th
Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ
Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in
Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb
Launches 2025 Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple Categories Announces First VLN® Partner Brands with Smoker Friendly Ready for Shipment in Q2 2025, Additional Partner VLN® Brands in Discussion MOCKSVILLE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the fourth quarter and year-ended December 31, 2024, and provided an update on recent business highlights. Fourth Quarter and Full Year 2024 Financial Results (compared to Thi
Remains on Path to Cash Positive Operations in Q1 2025Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple CategoriesMocksville, North Carolina--(Newsfile Corp. - November 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the third quarter ended September 30, 2024, and provided an update on recent business highlights.Third Quarter 2024 Financial Results (compared to Second Quarter 2024, except as noted)All figures reported below reflect continuing operations, excludin
Live Leadership Updates
Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a
Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO
BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e
CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea
Further Enhances 22nd Century Group's Deep Expertise in Plant-Based Biotechnology BUFFALO, N.Y., April 11, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced the appointment of Dr. Calvin Treat as Chief Scientific Officer, effective May 23, 2022. In this new role, Dr. Treat will lead the expanding scientific, research and technological operations of the company, leveraging its expertise, IP, and partnerships across all three of its alkaloid plant franchises toward becoming a global leader in specia
Carmines has submitted hundreds of PMTAs to the FDA and spearheaded the successful MRTPA submitted by 22nd Century Group (NASDAQ:XXII) that won an FDA marketing order in December 2021.COSTA MESA, CA / ACCESSWIRE / March 2, 2022 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium, nicotine-based, e-cigarette space, today announced the appointment of Edward Carmines, Ph.D., to its Board of Directors. Dr. Carmines is an accomplished scientist and regulatory affairs expert with extensive experience working with the Center for Tobacco Products at the U.S. Food and Drug Administration ("FDA"). In addition to an extraordinary record of success w
FDA's Rulemaking Process Could Make VLN® Menthol King Reduced Nicotine Cigarettes the Only Menthol Cigarette on the Market Opportunity to Accelerate FDA's Plan to Cap Nicotine in Cigarettes at Levels Already Achieved in 22nd Century's VLN® Products BUFFALO, N.Y., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, congratulates Dr. Robert Califf on his confirmation as FDA Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf is known to be a longtime proponent of innovative tobacco
BUFFALO, N.Y, Jan. 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced the appointment of James A. Mish to its Board of Directors (Board). The addition of Mr. Mish, who currently serves as Chief Executive Officer at 22nd Century, significantly enhances the Board's depth of experience in the commercialization of science-driven consumer products as the Company prepares to launch its first reduced nicotine content tobacco products and commercially modified hemp/cannabis plant lines. "Th
Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Company's Strategy, Technology Development, Commercialization, and Value Creation Efforts BUFFALO, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced the appointment of Anthony Johnson to its Board of Directors. Mr. Johnson is an accomplished life sciences and biotechnology executive leader with broad expertise in corporate strategy, technology development, marketing, and business development. Mr. Johnson will serve as a member of
To Date, 22nd Century Has Provided More Than 31 Million Variable Nicotine Content Research Cigarettes for Numerous Independent Scientific Studies Research on Nicotine Content Reduction in Cigarettes Underpins the FDA's Proposed Mandate to Reduce Nicotine Levels in All Cigarettes Sold in the U.S. to "Minimally or Non-Addictive" Levels, a Feat Already Achieved by VLN® Delivery of Research Cigarettes is to Support Nicotine Cap Mandate and is Unrelated to 22nd Century's Modified Risk Tobacco Product (MRTP) Application for VLN® Cigarettes BUFFALO, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a leading plant-based, biotechnology company that is focused on to